| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 79 | 2019 | 16193 | 1.020 |
Why?
|
| Paclitaxel | 22 | 2024 | 2099 | 0.730 |
Why?
|
| Doxorubicin | 33 | 2024 | 3138 | 0.690 |
Why?
|
| Taxoids | 15 | 2013 | 1008 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2024 | 16598 | 0.640 |
Why?
|
| Antineoplastic Agents, Phytogenic | 14 | 2003 | 896 | 0.480 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2002 | 744 | 0.470 |
Why?
|
| Receptor, ErbB-2 | 10 | 2019 | 2648 | 0.330 |
Why?
|
| Lacrimal Duct Obstruction | 3 | 2002 | 51 | 0.290 |
Why?
|
| Fluorouracil | 20 | 2012 | 1985 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2024 | 5427 | 0.250 |
Why?
|
| Cyclophosphamide | 22 | 2024 | 3231 | 0.250 |
Why?
|
| Neutropenia | 9 | 2023 | 1001 | 0.250 |
Why?
|
| Neoplasm Metastasis | 22 | 2019 | 5325 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 12 | 2024 | 5203 | 0.230 |
Why?
|
| Sirolimus | 4 | 2015 | 830 | 0.230 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2018 | 154 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 1372 | 0.220 |
Why?
|
| Middle Aged | 81 | 2024 | 90030 | 0.210 |
Why?
|
| Carboplatin | 2 | 2024 | 879 | 0.210 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2011 | 853 | 0.210 |
Why?
|
| Lacrimal Apparatus | 2 | 2002 | 186 | 0.210 |
Why?
|
| Adult | 74 | 2024 | 81540 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 490 | 0.200 |
Why?
|
| Receptors, Estrogen | 12 | 2012 | 2264 | 0.200 |
Why?
|
| Aged | 66 | 2024 | 73188 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2023 | 917 | 0.180 |
Why?
|
| Female | 88 | 2024 | 148456 | 0.180 |
Why?
|
| Gene Expression Profiling | 7 | 2012 | 5163 | 0.160 |
Why?
|
| Drug Administration Schedule | 17 | 2011 | 3538 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2019 | 5103 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2014 | 3972 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 2 | 2012 | 744 | 0.140 |
Why?
|
| Biomarkers, Tumor | 8 | 2014 | 10698 | 0.130 |
Why?
|
| Humans | 93 | 2024 | 270825 | 0.130 |
Why?
|
| Metaplasia | 2 | 2015 | 386 | 0.130 |
Why?
|
| Imatinib Mesylate | 2 | 2018 | 1691 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2024 | 2379 | 0.130 |
Why?
|
| Disease-Free Survival | 17 | 2014 | 10250 | 0.130 |
Why?
|
| Mastectomy | 3 | 2013 | 1547 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 8 | 2011 | 4519 | 0.120 |
Why?
|
| Tamoxifen | 7 | 2010 | 907 | 0.120 |
Why?
|
| Trastuzumab | 7 | 2019 | 736 | 0.120 |
Why?
|
| Drug Carriers | 4 | 2002 | 336 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2014 | 9083 | 0.110 |
Why?
|
| Estrogen Antagonists | 3 | 2001 | 219 | 0.110 |
Why?
|
| Liposomes | 5 | 2002 | 713 | 0.110 |
Why?
|
| Bone Neoplasms | 4 | 2012 | 2667 | 0.110 |
Why?
|
| Procollagen | 1 | 2012 | 32 | 0.110 |
Why?
|
| Mesoderm | 1 | 2015 | 397 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2012 | 1327 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 1014 | 0.100 |
Why?
|
| Sarcoma | 1 | 2023 | 1839 | 0.100 |
Why?
|
| Treatment Outcome | 26 | 2018 | 33821 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2014 | 3394 | 0.100 |
Why?
|
| Vinblastine | 3 | 2003 | 462 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 3 | 2019 | 231 | 0.100 |
Why?
|
| Thiophenes | 2 | 2003 | 149 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2013 | 10350 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 310 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2011 | 770 | 0.090 |
Why?
|
| Guanidines | 3 | 1995 | 61 | 0.090 |
Why?
|
| Genes, erbB-2 | 2 | 2011 | 228 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 388 | 0.090 |
Why?
|
| Infusions, Intravenous | 6 | 2005 | 1437 | 0.090 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2002 | 146 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 315 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 210 | 0.080 |
Why?
|
| Antineoplastic Agents | 11 | 2008 | 14679 | 0.080 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 346 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2008 | 67 | 0.080 |
Why?
|
| Combined Modality Therapy | 13 | 2012 | 9040 | 0.080 |
Why?
|
| Neoplasm Staging | 14 | 2015 | 13977 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2013 | 605 | 0.070 |
Why?
|
| Uracil | 2 | 2010 | 67 | 0.070 |
Why?
|
| Survival Rate | 9 | 2019 | 12515 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2011 | 1322 | 0.070 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 693 | 0.070 |
Why?
|
| Radiometry | 1 | 2013 | 1018 | 0.070 |
Why?
|
| Aminopterin | 1 | 2006 | 32 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2009 | 218 | 0.070 |
Why?
|
| Piperidines | 2 | 2003 | 1090 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2009 | 612 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2012 | 6484 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 4980 | 0.060 |
Why?
|
| Lung Neoplasms | 8 | 2002 | 11775 | 0.060 |
Why?
|
| Neoplasms | 5 | 2003 | 15852 | 0.060 |
Why?
|
| Deoxycytidine | 3 | 2012 | 1377 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2023 | 13361 | 0.060 |
Why?
|
| Survival Analysis | 10 | 2010 | 9304 | 0.060 |
Why?
|
| Carcinoma | 2 | 2011 | 2627 | 0.060 |
Why?
|
| Leucovorin | 2 | 2010 | 343 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2005 | 426 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 214 | 0.060 |
Why?
|
| Prognosis | 10 | 2015 | 22452 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1995 | 104 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2006 | 366 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6248 | 0.060 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 173 | 0.050 |
Why?
|
| Genomics | 2 | 2011 | 2818 | 0.050 |
Why?
|
| Receptors, Progesterone | 4 | 2012 | 1645 | 0.050 |
Why?
|
| Pyrazines | 1 | 2006 | 524 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1547 | 0.050 |
Why?
|
| Algorithms | 2 | 2011 | 3905 | 0.050 |
Why?
|
| Quinolines | 1 | 2005 | 402 | 0.050 |
Why?
|
| Follow-Up Studies | 9 | 2015 | 15239 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2006 | 1133 | 0.050 |
Why?
|
| Time Factors | 8 | 2010 | 13103 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2006 | 484 | 0.050 |
Why?
|
| Cisplatin | 6 | 2006 | 2493 | 0.050 |
Why?
|
| Estradiol | 1 | 2004 | 885 | 0.050 |
Why?
|
| Heart | 3 | 2002 | 1211 | 0.040 |
Why?
|
| Tears | 1 | 2001 | 165 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2000 | 234 | 0.040 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 7810 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 5436 | 0.040 |
Why?
|
| Bevacizumab | 2 | 2015 | 959 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2153 | 0.040 |
Why?
|
| Estrogens | 1 | 2003 | 845 | 0.040 |
Why?
|
| Benzamides | 2 | 2019 | 1883 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2002 | 315 | 0.040 |
Why?
|
| Everolimus | 2 | 2011 | 438 | 0.040 |
Why?
|
| Forecasting | 2 | 2011 | 707 | 0.040 |
Why?
|
| Epirubicin | 2 | 2012 | 159 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2000 | 160 | 0.040 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 30940 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2006 | 1732 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 2489 | 0.040 |
Why?
|
| Vidarabine | 1 | 2003 | 1383 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 5084 | 0.040 |
Why?
|
| Fibrosis | 1 | 2001 | 744 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 4789 | 0.040 |
Why?
|
| Capecitabine | 2 | 2012 | 390 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 2266 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1999 | 235 | 0.040 |
Why?
|
| Signal Transduction | 4 | 2024 | 12206 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2014 | 2286 | 0.030 |
Why?
|
| Remission Induction | 4 | 2005 | 3645 | 0.030 |
Why?
|
| Nausea | 4 | 2006 | 540 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1590 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3666 | 0.030 |
Why?
|
| Drug Resistance | 2 | 1994 | 615 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4329 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2006 | 6983 | 0.030 |
Why?
|
| Cytokines | 1 | 2004 | 2836 | 0.030 |
Why?
|
| Agranulocytosis | 3 | 2006 | 83 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2013 | 2847 | 0.030 |
Why?
|
| Adenocarcinoma | 6 | 2001 | 7936 | 0.030 |
Why?
|
| Patient Selection | 3 | 2010 | 2040 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 1400 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2003 | 2359 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1995 | 283 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1994 | 59 | 0.030 |
Why?
|
| Male | 17 | 2019 | 128398 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2005 | 2312 | 0.030 |
Why?
|
| Methotrexate | 2 | 2010 | 1026 | 0.030 |
Why?
|
| Deficiency Diseases | 1 | 1973 | 12 | 0.030 |
Why?
|
| Fever | 3 | 2002 | 515 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1973 | 26 | 0.030 |
Why?
|
| Etoposide | 3 | 2006 | 905 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 531 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 1994 | 276 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2012 | 94 | 0.030 |
Why?
|
| Peptides | 2 | 2012 | 1529 | 0.030 |
Why?
|
| Disease Progression | 4 | 2006 | 6892 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2004 | 1618 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2003 | 1345 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 1994 | 267 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2012 | 191 | 0.020 |
Why?
|
| Pyridines | 1 | 2019 | 1312 | 0.020 |
Why?
|
| Interleukin-12 | 2 | 2004 | 267 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 15859 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2010 | 10 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 642 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2413 | 0.020 |
Why?
|
| Genes | 1 | 2012 | 611 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2011 | 180 | 0.020 |
Why?
|
| Tegafur | 1 | 2010 | 51 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 1233 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1566 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2009 | 94 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 206 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2011 | 339 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1820 | 0.020 |
Why?
|
| Young Adult | 3 | 2015 | 22035 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 450 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3492 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2008 | 2314 | 0.020 |
Why?
|
| Lymphatic Metastasis | 3 | 2005 | 4967 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 1725 | 0.020 |
Why?
|
| Endometrium | 2 | 2003 | 469 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2006 | 2049 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 724 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 314 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 1065 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 1322 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 738 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1994 | 1442 | 0.020 |
Why?
|
| Liver | 2 | 2013 | 3123 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 5184 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2010 | 6828 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1913 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 753 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2002 | 4774 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2004 | 2346 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2014 | 39679 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 153 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 2349 | 0.020 |
Why?
|
| Alopecia | 1 | 2006 | 123 | 0.020 |
Why?
|
| Adolescent | 4 | 2011 | 32508 | 0.020 |
Why?
|
| Adenoviruses, Human | 1 | 2006 | 191 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2006 | 245 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2005 | 125 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2006 | 395 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 3073 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1994 | 3859 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 226 | 0.020 |
Why?
|
| Anthraquinones | 1 | 1984 | 28 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 1571 | 0.010 |
Why?
|
| Esophageal Diseases | 1 | 1985 | 79 | 0.010 |
Why?
|
| Transgenes | 1 | 2006 | 589 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 269 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 335 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2008 | 669 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1424 | 0.010 |
Why?
|
| Bortezomib | 1 | 2006 | 553 | 0.010 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 44 | 0.010 |
Why?
|
| Sulindac | 1 | 2003 | 55 | 0.010 |
Why?
|
| Gene Expression | 1 | 2012 | 3679 | 0.010 |
Why?
|
| Antibody Formation | 2 | 1995 | 388 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2669 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2003 | 111 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 171 | 0.010 |
Why?
|
| Graft vs Tumor Effect | 1 | 2003 | 143 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 812 | 0.010 |
Why?
|
| Abatacept | 1 | 2002 | 43 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 1236 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2011 | 2118 | 0.010 |
Why?
|
| Postmenopause | 1 | 2004 | 380 | 0.010 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 117 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 478 | 0.010 |
Why?
|
| Intubation | 1 | 2002 | 42 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3653 | 0.010 |
Why?
|
| Risk Factors | 2 | 2010 | 17814 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2005 | 769 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3415 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 663 | 0.010 |
Why?
|
| Antigens | 1 | 2002 | 288 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2002 | 171 | 0.010 |
Why?
|
| Prodrugs | 1 | 2003 | 226 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 254 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 956 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2399 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 474 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 531 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 4882 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 170 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2006 | 1010 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 481 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 617 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1568 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1884 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 1070 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 4326 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 7465 | 0.010 |
Why?
|
| Anemia | 1 | 2006 | 730 | 0.010 |
Why?
|
| Melphalan | 1 | 2003 | 877 | 0.010 |
Why?
|
| Epitopes | 1 | 2002 | 711 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 2001 | 192 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2003 | 698 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 609 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1076 | 0.010 |
Why?
|
| Frail Elderly | 1 | 2000 | 123 | 0.010 |
Why?
|
| Apgar Score | 1 | 1999 | 55 | 0.010 |
Why?
|
| Disease | 1 | 2000 | 159 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2002 | 679 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 1184 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1067 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1617 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 2716 | 0.010 |
Why?
|
| Prednisone | 1 | 2001 | 1039 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1985 | 1858 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 1435 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2002 | 1269 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2002 | 1021 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1277 | 0.010 |
Why?
|
| Antiemetics | 1 | 1998 | 122 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 4067 | 0.010 |
Why?
|
| Birth Weight | 1 | 1999 | 350 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 2616 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 1989 | 5567 | 0.010 |
Why?
|
| Edema | 1 | 1998 | 263 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 2002 | 750 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 3033 | 0.010 |
Why?
|
| Vincristine | 1 | 2001 | 1572 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 1232 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1999 | 578 | 0.010 |
Why?
|
| Radiography | 1 | 2001 | 1988 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6185 | 0.010 |
Why?
|
| Complement C4 | 1 | 1995 | 14 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 2466 | 0.010 |
Why?
|
| Isoantigens | 1 | 1995 | 67 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 1695 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 747 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1999 | 580 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1995 | 345 | 0.010 |
Why?
|
| Complement C3 | 1 | 1995 | 84 | 0.010 |
Why?
|
| Complement Activation | 1 | 1995 | 95 | 0.010 |
Why?
|
| Fetus | 1 | 1999 | 674 | 0.010 |
Why?
|
| Gestational Age | 1 | 1999 | 1145 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 1984 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2000 | 1047 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1994 | 49 | 0.010 |
Why?
|
| Texas | 1 | 2005 | 6411 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 57 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1998 | 520 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1984 | 435 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 585 | 0.010 |
Why?
|
| Magnesium | 1 | 1994 | 173 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 1506 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1994 | 67 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1973 | 14 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 1973 | 54 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1973 | 79 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1999 | 737 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 4956 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 809 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 2805 | 0.010 |
Why?
|
| Animals | 2 | 1994 | 62801 | 0.010 |
Why?
|
| Hypotension | 1 | 1994 | 236 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 5531 | 0.010 |
Why?
|
| Canada | 1 | 1973 | 428 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1973 | 358 | 0.010 |
Why?
|
| United States | 1 | 2008 | 15962 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2000 | 1380 | 0.010 |
Why?
|
| Age Factors | 1 | 2000 | 5485 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2003 | 9430 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 3067 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 4735 | 0.010 |
Why?
|
| Pedigree | 1 | 1973 | 1981 | 0.000 |
Why?
|
| Thrombocytopenia | 2 | 1984 | 871 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 1999 | 4385 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 1666 | 0.000 |
Why?
|
| Phosphoramide Mustards | 1 | 1988 | 37 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1995 | 2434 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1984 | 4980 | 0.000 |
Why?
|
| Pregnancy | 1 | 1999 | 8034 | 0.000 |
Why?
|
| Peptichemio | 1 | 1985 | 12 | 0.000 |
Why?
|
| Esophageal Fistula | 1 | 1985 | 30 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1973 | 2089 | 0.000 |
Why?
|
| Esophageal Stenosis | 1 | 1985 | 90 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1984 | 228 | 0.000 |
Why?
|
| Myocardium | 1 | 1989 | 1250 | 0.000 |
Why?
|
| Esophagitis | 1 | 1985 | 210 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1995 | 3533 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1984 | 427 | 0.000 |
Why?
|
| Mice | 1 | 1994 | 36026 | 0.000 |
Why?
|